Summary - IMAB - NASDAQ - Weiss Ratings

U

I-Mab IMAB

$0.855 $0.00981.16% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$0.595 - $2.00

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Biotechnology Health Care Pharmaceutical

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

I-Mab (NASDAQ:IMAB) Short Interest Down 64.9% in March

4/17/2025 - MarketBeat

After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)

4/14/2025 - Zacks Investment Research

After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)

4/11/2025 - Zacks Investment Research

I-Mab's (IMAB) Buy Rating Reiterated at Needham & Company LLC

4/6/2025 - MarketBeat

HC Wainwright Has Lowered Expectations for I-Mab (NASDAQ:IMAB) Stock Price

4/6/2025 - MarketBeat

I-Mab's Transformative Year: Financial and Strategic Highlights

4/5/2025 - TipRanks Financial Blog

I-Mab Positions for Growth with U.S. Focus and Innovative Cancer Treatments

4/4/2025 - TipRanks Financial Blog

I-Mab price target lowered to $7 from $8 at H.C. Wainwright

4/4/2025 - TipRanks Financial Blog

I-Mab price target lowered by $1 at H.C. Wainwright, here's why

4/4/2025 - The Fly

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

4/3/2025 - GuruFocus

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

4/3/2025 - Globe Newswire

I-Mab (NASDAQ:IMAB) Trading 0.6% Higher - Still a Buy?

3/29/2025 - MarketBeat

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

3/26/2025 - GuruFocus

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

3/26/2025 - Globe Newswire

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

3/21/2025 - GuruFocus

I-Mab Receives Nasdaq Deficiency Notice for Minimum Bid Price

3/21/2025 - TipRanks Financial Blog

I-Mab receives Nasdaq notice over non-compliance with minimum bid price rule

3/21/2025 - SeekingAlpha.com: All News

I-Mab receives Nasdaq notice over non-compliance with minimum bid price rule

3/21/2025 - Seeking Alpha - Healthcare

I-Mab receives Nasdaq deficiency notice

3/21/2025 - TipRanks Financial Blog

I-Mab receives Nasdaq deficiency notice

3/21/2025 - The Fly

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

3/21/2025 - Globe Newswire

Short Interest in I-Mab (NASDAQ:IMAB) Rises By 20.0%

3/7/2025 - MarketBeat

I-Mab rises after update on early-stage trial for gastric cancer therapy

3/7/2025 - Seeking Alpha - Healthcare

I-Mab announces accelerated givastomig Phase 1b study progress

3/7/2025 - TipRanks Financial Blog

I-Mab announces accelerated givastomig Phase 1b study progress

3/7/2025 - The Fly

Income Statement

Total Revenue (TTM)

--

EBITDA (TTM)

--

EBIT (TTM)

--

Net Income (TTM)

--

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

--

Cash from Investing (TTM)

--

Cash from Financing (TTM)

--

Net Change in Cash (TTM)

--

Filings

Filing Date

Thursday, April 3, 2025

Period Date

Tuesday, December 31, 2024

Next Filing

Week of Aug 25 and 29 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Apr 04, 2025 - $0.595

52-week High

Jun 04, 2024 - $2.00

Valuation

Market Cap

$68.88M - Micro Cap

Enterprise Value

Price/Sales (TTM)

--

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

www.i-mabbiopharma.com

Phone Number

240 745 6330

Address

2440 Research Boulevard
Rockville, MD 20850

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. It is developing givastomig, a bispecific antibody, which is in... more